Skip to main content
Gossamer Bio, Inc. logo

Gossamer Bio, Inc. — Investor Relations & Filings

Listed
Ticker · GOSS ISIN · US38341P1021 LEI · 549300ZOC0N2W6PSFR58 US Manufacturing
Open in API
Filings indexed 430 across all filing types
Latest filing 2026-07-01 Capital/Financing Update
Country US United States of America
Listing US GOSS · 7 venues

About Gossamer Bio, Inc.

https://www.gossamerbio.com/

Gossamer Bio, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of its lead investigational product, seralutinib. The company is developing this therapy for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). Seralutinib is an inhaled inhibitor of PDGFRα/β, CSF1R, and c-KIT, designed for delivery via a dry powder inhaler. The company's goal is to address the needs of patients with these rare diseases.

Recent filings

Filing Released Lang Actions
8-K
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K current report filed with the SEC by Gossamer Bio, Inc., dated July 1, 2026. The key content involves an announcement of terms related to convertible senior secured notes and warrants, specifically the conversion rate and exercise price. The document includes a press release as an exhibit but does not contain detailed financial statements or comprehensive financial analysis. Form 8-K filings are typically used for current event announcements such as financing updates or material corporate events. Here, the disclosure relates to a financing instrument (convertible notes), indicating a capital or financing update rather than a full report or earnings release. The document length is only 3475 characters, further supporting it is an announcement rather than a full report. Therefore, the document best fits the Capital/Financing Update category (CAP).
2026-07-01 English
8-K
Regulatory Filings Classification · 100% confidence The document is a Form 8-K filed with the SEC by Gossamer Bio, Inc., dated June 17, 2026. It reports on a recent event: the final tender results of a convertible notes exchange offer and related matters, including a press release attached as Exhibit 99.1. The document explicitly mentions that the information is pursuant to the Securities Exchange Act of 1934. The content focuses on disclosure of a financing transaction's status rather than an earnings announcement, management discussion, or full annual/interim report. It lacks substantive financial statement data and is mainly an event-driven regulatory filing. Therefore, it fits best under the 'Regulatory Filings (RNS)' category since it is a regulatory disclosure report updating investors about a significant transaction rather than a detailed primary financial report or announcement of a report or meeting.
2026-06-17 English
DEF 14A
Proxy Solicitation & Information Statement
2026-06-09 English
8-K
Capital/Financing Update Classification · 84% confidence The document is a Form 8-K “Current Report” describing the early settlement of an exchange offer, the issuance of new 7.50% Convertible Senior Secured First Lien Notes due 2030, new shares of common stock, prefunded warrants and purchase warrants, and entry into related indentures and agreements. This is a detailed capital structure and financing transaction update, matching the “Capital/Financing Update” definition.
2026-06-04 English
8-K
Declaration of Voting Results & Voting Rights Announcements Classification · 98% confidence The document is an SEC Form 8-K reporting Item 5.07 Submission of Matters to a Vote of Security Holders. It lists the vote counts (for, against, withheld, broker non-votes) for director elections, auditor ratification, and advisory compensation vote at the annual meeting. This matches the definition of Declaration of Voting Results & Voting Rights Announcements (DVA).
2026-06-04 English
8-K
Capital/Financing Update Classification · 85% confidence The document is a U.S. SEC Form 8-K “Current Report” under Item 8.01 “Other Events,” describing the extension of the early tender deadline for an exchange offer and consent solicitation relating to the company’s 5.00% Convertible Senior Notes due 2027. This is an update on the company’s financing activity and capital structure. Therefore, it best fits the “Capital/Financing Update” category.
2026-06-02 English

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.